Key Market Takeaways
• Philip Morris International (PM): +14.2% YTD as IQOS and ZYN drive 38% of group revenue, up from 32% in 2025.
• British American Tobacco (BATS.L): Steady at +6.8% YTD; Modern Oral category up 65.9% in H1, offsetting combustibles decline.
• RELX Group (603649.SS): -11.4% YTD as China STMA summons and TPD3 exposure weigh on Shenzhen A-shares.
• Market Shift: Investor preference tilting from disposable-play manufacturers to refillable/pod-system and oral nicotine platforms.
The nicotine sector is seeing a valuation divergence not seen since the original FDA deeming rule in 2016.
Philip Morris International: The Smoke-Free Conversion Play
Philip Morris International has emerged as the clear beneficiary of the industry’s pivot toward reduced-risk products. After surpassing $40 billion in total net revenue for the trailing twelve months as of July 2026, the company now generates approximately 38% of sales from its smoke-free portfolio, led by IQOS heated tobacco and ZYN nicotine pouches.
Financial Performance Snapshot
| Metric | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Total Net Revenue | $19.1B | $20.7B | +8.4% |
| Smoke-Free Revenue Share | 32% | 38% | +6pp |
| IQOS User Base (Global) | 30.2M | 34.5M | +14.2% |
| ZYN Volume (US) | 155M cans | 189M cans | +21.9% |
| Gross Margin | 63.2% | 64.8% | +1.6pp |
PMI’s stock price traded at $118.40 on the NYSE as of August 11, representing a 14.2% year-to-date gain and a forward P/E of 21.4x. The valuation premium over legacy tobacco peers reflects the market’s increasing confidence in the smoke-free transition. Analysts at Jefferies have a $135 target, citing ZYN’s expansion into 12 additional EU markets planned for Q4 2026.
“PMI is the only large-cap tobacco name where you are essentially buying a growth story wrapped in a dividend aristocrat shell. The ZYN campus in Lexington, Kentucky is now running at 92% capacity utilization, and the second production line commissioning in Q3 will add another 400 million cans annually.”
— Jefferies Equity Research, July 2026
The IQOS ILUMA platform continues to gain traction in Japan, where heated tobacco now represents 33.7% of the total nicotine market. PMI’s Japan revenue grew 11.3% in H1 2026, with heated tobacco units capturing 28.1% of the combustible cigarette volume decline. The ILUMA i device, launched in April 2026, has achieved a 19.4% conversion rate among existing IQOS users within its first 90 days.
PMI’s boardroom strategy focuses on smoke-free conversion while maintaining dividend commitments.
British American Tobacco: The Diversified Portfolio Defense
British American Tobacco presents a more nuanced picture. The London-listed giant is navigating a dual transition: managing combustibles decline while scaling next-generation products. The stock traded at 3,248p on the LSE as of August 11, up 6.8% YTD, with the company maintaining its progressive dividend policy at 231p per share.
H1 2026 Performance Breakdown
| Category | H1 2026 Revenue | H1 2025 Revenue | Growth |
|---|---|---|---|
| New Categories (Vuse, Velo, Vuse) | £1.82B | £1.54B | +18.2% |
| Modern Oral (Velo) | £412M | £248M | +65.9% |
| Vaping (Vuse) | £1.18B | £1.09B | +8.3% |
| Combustibles | £11.2B | £11.6B | -3.4% |
| Total Group | £13.02B | £13.14B | -0.9% |
BAT’s strategy rests on three pillars: Vuse in vaping, Velo in oral nicotine, and potentially heated tobacco through its iFuse platform. The Velo Modern Oral category has been the standout performer, with 65.9% growth driven by the UK, Sweden, and expanding German market. The company invested £280 million in its Velo production facility in Krakow, Poland, which is now operational and will serve as the primary supply hub for European markets.
However, BAT faces headwinds. The UK disposable vape ban, effective from June 2026, has compressed Vuse volumes in its largest single market by 8.3%. Additionally, TPD3’s proposed flavor restrictions could impact Vuse’s flavored cartridge range, which currently represents 42% of EU Vuse sales. Management has publicly stated it is developing a flavor-compliant Vuse line for potential TPD3 requirements.
“BAT’s diversification is both its strength and its drag. Modern Oral is growing at 65% but still represents just 3% of group revenue. The real story is the 3.4% combustibles decline outpacing next-gen growth, creating a headline revenue contraction that obscures the underlying portfolio transformation.”
— Morgan Stanley European Tobacco Coverage, August 2026
TPD3 uncertainty is the single largest overhang on BAT’s near-term valuation.
RELX Group: The Shenzhen Squeeze
RELX Group, listed on the Shanghai Stock Exchange as 603649.SS, faces a more challenging environment. The stock traded at ¥128.40 on August 11, down 11.4% YTD, underperforming both A-share consumer staples and global nicotine peers. The dual pressure from China’s STMA regulatory tightening and international market headwinds has compressed RELX’s valuation to 14.2x trailing P/E, a 35% discount to PMI.
RELX H1 2026 Metrics
| Metric | H1 2026 | Y/Y Change | Context |
|---|---|---|---|
| Revenue (RMB) | ¥6.8B | -4.2% | International offset domestic growth |
| Domestic Sales | ¥2.1B | +18.6% | Growth driven by closed-system pods |
| International Sales | ¥4.7B | -11.8% | SE Asia ban impact + EU TPD3 uncertainty |
| Market Cap (A-shares) | ¥58.2B | -14.8% | Widest discount to intrinsic value since IPO |
The STMA summons of iMiracle Technology (Elf Bar’s parent) has created indirect pressure on RELX. While RELX operates primarily in the closed-system pod category, the broader regulatory tightening has triggered a sector-wide risk reassessment. Shenzhen-based analysts note that RELX’s domestic license provides a competitive moat that smaller players lack, but international exposure remains the key vulnerability.
RELX has responded by accelerating its entry into the Middle Eastern market, with a distribution partnership in Saudi Arabia signed in July 2026. The company is also developing a TPD3-compliant product line for potential EU relaunch in 2027, focusing on tobacco-only and menthol-only flavors with nicotine concentrations capped at 17mg/mL.
Medium Risk: International Revenue Dependency
RELX generates 69% of revenue from international markets, but Southeast Asian bans (Vietnam, Thailand) and EU TPD3 uncertainty have created a $420 million revenue hole in H2 2026 projections. The Saudi Arabia partnership and Middle Eastern expansion are critical to filling this gap, but execution risk remains high given the 6-9 month timeline for regulatory approval and market penetration.
Comparative Valuation Matrix
The valuation divergence across the nicotine sector’s three largest publicly traded players reveals distinct investor risk assessments:
| Company | Market Cap | P/E (FWD) | Div Yield | Smoke-Free Rev % | YTD Stock Change |
|---|---|---|---|---|---|
| PMI (PM) | $184.2B | 21.4x | 3.8% | 38% | +14.2% |
| BAT (BATS.L) | £70.4B | 11.2x | 7.1% | 14% | +6.8% |
| RELX (603649.SS) | ¥58.2B | 14.2x | 1.9% | 100% (pure-play) | -11.4% |
| Altria (MO) | $96.8B | 10.8x | 8.2% | 6% | +3.1% |
| Smooore (6969.HK) | HK$42.1B | 18.6x | 1.2% | 100% (OEM) | -18.2% |
The market is clearly rewarding PMI’s diversified smoke-free transition with a premium multiple, while discounting pure-play exposure where regulatory risk is concentrated. Smooore International, the OEM giant that manufactures for Elf Bar and other brands, has been the hardest hit, with its stock down 18.2% YTD as the STMA summons threatens to disrupt its largest client relationship.
Supply Chain Implications: Where the Money Is Moving
The stock market signals are filtering down to supply chain decisions. Three distinct capital allocation trends are emerging:
- Refillable Pod Infrastructure: PMI’s Lexington ZYN campus and BAT’s Krakow Velo facility represent $1.4 billion in combined capital expenditure for oral nicotine manufacturing capacity. Component suppliers specializing in pod-system precision engineering are seeing order books extend 18-24 months.
- Disposable Consolidation: The STMA summons of iMiracle and resulting Smooore stock decline are accelerating consolidation in the disposable segment. Shenzhen OEMs in the Baoan district are reporting a 22% decline in new client inquiries since July 2026, while white-label orders from tier-2 brands have dropped 35%.
- TPD3 Preparation Spend: European distributors are investing heavily in compliance infrastructure. BAT, PMI, and independent vape brands collectively spent an estimated €120 million in H1 2026 on product reformulation, packaging redesign, and flavor-substance testing in anticipation of TPD3 requirements.
“The capital expenditure cycle has shifted decisively toward refillable and oral nicotine platforms. For every dollar invested in disposable capacity in 2025, three dollars are now being allocated to pod systems and ZYN-style manufacturing. This is not a cyclical shift; it is structural.”
— Barclays Capital Markets, Tobacco Sector Capital Allocation Report, August 2026
Refillable pod manufacturing capacity is expanding as investors reward diversified nicotine platforms.
Investor Outlook: Positioning for H2 2026
For investors and industry operators, the H2 2026 nicotine stock landscape presents both opportunity and risk. The sector is bifurcating into winners and losers based on regulatory readiness, product portfolio diversification, and geographic exposure.
Strategic Recommendations by Player Type
- For Institutional Investors: PMI remains the highest-conviction overweight in the nicotine sector, with ZYN’s 21.9% volume growth and IQOS expansion into 14 new markets providing clear earnings visibility. BAT offers value exposure at 11.2x P/E with a 7.1% dividend yield, but TPD3 resolution is a prerequisite for re-rating.
- For Supply Chain Operators: Diversify toward refillable pod component manufacturing. The 3:1 capex ratio favoring pods over disposables is accelerating, and suppliers with TPD3-compliant component certifications will command pricing premiums through 2028.
- For Retail Investors: RELX at 14.2x P/E represents a potential value opportunity if the Saudi Arabia partnership delivers on its $180 million annual revenue target and STMA enforcement remains focused on disposable manufacturers rather than closed-system pod companies.
- For Industry Operators: The disposable segment is entering a structural decline. Brands relying exclusively on single-use products should accelerate R&D investment in refillable platforms or face margin compression as regulatory compliance costs rise and market access narrows.
Bottom Line: The nicotine stock market in H2 2026 is no longer a monolithic sector. PMI’s smoke-free premium, BAT’s diversified defense, and RELX’s emerging-market squeeze represent three distinct investment theses. Investors and operators who align their capital allocation with the refillable/oral nicotine transition will outperform those still anchored to the disposable-era playbook.
BAT Earnings
RELX 603649
Nicotine Sector
Smoke-Free Transition
IQOS Performance
ZYN Volume
Vuse Market Share
TPD3 Impact
STMA Regulatory
Supply Chain Shift
Refillable Pods
Disposable Vape Decline
Published by VTank Blog for market analysis purposes. Data sources include NYSE/LSE/SSE filings, company H1 2026 earnings reports, Jefferies, Morgan Stanley, and Barclays equity research notes. Stock prices as of market close August 11, 2026.
